A New Vaccine for Advanced Pancreatic Cancer
An mRNA vaccine that works against KRAS mutations is being tested with and without immunotherapy for advanced or metastatic pancreatic cancer.
An mRNA vaccine that works against KRAS mutations is being tested with and without immunotherapy for advanced or metastatic pancreatic cancer.
Dr. Manuel Hidalgo explains the COMBAT trial, which combines immunotherapy, a checkpoint inhibitor, and chemotherapy to attack pancreatic cancer.
Dr. Deirdre Cohen’s research into the pancreatic microbiome has found that gut bacteria may directly influence the effectiveness of immunotherapy.
When standard treatment did not work for Roy Vinke’s pancreatic cancer, he had genomic profiling done. A mutation was found, changing his treatment plan.
Dr. Johanna Bendell explains the value of molecular profiling. It can indicate which type of chemotherapy will be more successful on your tumor.
This trial is active, but no longer recruiting participants. Pancreatic neuroendocrine tumors (P-NETs) make up less than 5 percent of all pancreatic cancers. Unlike pancreatic ductal adenocarcinomas (PDAs), P-NETs originate in the hormone-making islet cells of the pancreas, respond to different treatments, and have an overall survival rate higher than PDAs. In a clinical trial,…
The Lustgarten Foundation shares the story that Keytruda (pembrolizumab) is a runner-up in Science magazine’s Breakthrough of the year.
A clinical trial is testing chemotherapy that enhances the action of two immunotherapy drugs and SBRT to stop locally advanced pancreatic cancer.
A clinical trial looks at immunotherapy plus vitamin D plus standard chemotherapy before surgery to remove pancreatic cancer.
Immunotherapy with Keytruda (pembrolizumab) is approved for use in cancer patients with certain genetic defects in their tumors.